Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis

BACKGROUND: Intraperitoneal-free cancer cells are considered as an important prognostic tool in gastric and ovarian cancer. However, their significance in colorectal cancer remains more controversial. OBJECTIVE: This study aimed to determine the role of intraperitoneal-free cancer cells as a prognostic tool in the outcome in colorectal peritoneal carcinomatosis treated with curative intent by complete cytoreductive surgery. DESIGN: This study is an analysis of a prospectively maintained database. PATIENTS: Between 1991 and 2012, all patients treated in a single institution for colorectal peritoneal carcinomatosis by complete cytoreductive surgery with peritoneal cytology available were evaluated. Peritoneal cytology was stained in the conventional way (May Grumwald Giemsa). RESULTS: Among a population of 162 patients treated for colorectal peritoneal carcinomatosis by complete cytoreductive surgery, 38 presented positive intraperitoneal-free cancer cells (23.5%). Systemic chemotherapy was administered to 135 patients (85%) during the preoperative course. Median follow-up was 34.5 months. Median overall survival was 19 and 44 months for positive and negative intraperitoneal-free cancer cells (p = 0.018). In multivariate analysis, Peritoneal Carcinomatosis Index and positive intraperitoneal-free cancer cells were significant prognostic factors of overall survival (HR, 2.3 (1.18–4.52), p = 0.014; HR, 1.9 (1.08–3.38), p = 0.027). LIMITATIONS: Retrospective analysis and the long period were limitations of study. CONCLUSION: Along with the Peritoneal Carcinomatosis Index, intraperitoneal-free cancer cells are a strong prognostic factor for patients treated with curative intent for colorectal peritoneal carcinomatosis by complete cytoreductive surgery. The presence of intraperitoneal-free cancer cells should lead to the consideration of different treatment strategies such as extensive intraperitoneal lavage, targeted intraperitoneal therapies, or repeated intraperitoneal chemotherapy.

[1]  T. Chua,et al.  The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis , 2014, Annals of Surgical Oncology.

[2]  E. Cotte,et al.  Pathological Response to Neoadjuvant Chemotherapy: A New Prognosis Tool for the Curative Management of Peritoneal Colorectal Carcinomatosis , 2014, Annals of Surgical Oncology.

[3]  E. Levine,et al.  Metastatic Colorectal Cancer: Survival Comparison of Hepatic Resection Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2014, Annals of Surgical Oncology.

[4]  L. Zitvogel,et al.  Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab , 2014, BMC Cancer.

[5]  E. Cotte,et al.  Intra-operative peritoneal lavage for colorectal cancer. , 2014, World journal of gastroenterology.

[6]  B. Moran,et al.  Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  M. Ducreux,et al.  Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy? , 2013, Annals of surgery.

[8]  E. Cotte,et al.  Intraperitoneal free cancer cells in non‐gynaecological adenocarcinomas: a reproducibility study , 2012, Cytopathology : official journal of the British Society for Clinical Cytology.

[9]  T. Fujiwara,et al.  Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer. , 2012, Biochemical and biophysical research communications.

[10]  M. Torrisi,et al.  Free peritoneal tumor cells detection in gastric and colorectal cancer patients , 2012, Journal of surgical oncology.

[11]  F. Granath,et al.  Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer , 2012, The British journal of surgery.

[12]  B. Gückel,et al.  Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. , 2011, International journal of oncology.

[13]  S. Msika,et al.  Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy , 2010, Cancer.

[14]  M. Pocard,et al.  A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma Appendix , 2010, Annals of surgery.

[15]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[16]  Y. Doki,et al.  Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. , 2010, Anticancer research.

[17]  H. Nagawa,et al.  Prognostic Value of Peritoneal Cytology and the Combination of Peritoneal Cytology and Peritoneal Dissemination in Colorectal Cancer , 2009, Diseases of the colon and rectum.

[18]  H. Baba,et al.  Extensive Intraoperative Peritoneal Lavage as a Standard Prophylactic Strategy for Peritoneal Recurrence in Patients with Gastric Carcinoma , 2009, Annals of surgery.

[19]  M. Yano,et al.  Long-Term Prognostic Value of Conventional Peritoneal Lavage Cytology in Patients Undergoing Curative Colorectal Cancer Resection , 2009, Diseases of the colon and rectum.

[20]  K. Yamashita,et al.  Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer , 2009, The British journal of surgery.

[21]  D. Elias,et al.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Moorthy,et al.  Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma , 2008, The British journal of surgery.

[23]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[24]  P. Hewett,et al.  Identification of Early-Stage Colorectal Cancer Patients at Risk of Relapse Post-Resection by Immunobead Reverse Transcription-PCR Analysis of Peritoneal Lavage Fluid for Malignant Cells , 2006, Clinical Cancer Research.

[25]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[26]  M. Steurer,et al.  Improving tumor cell detection in pleural effusions by interphase cytogenetics , 2003, Cytometry. Part B, Clinical cytometry.

[27]  M. Ogawa,et al.  Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells , 2002, Gastric Cancer.

[28]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[30]  H. Ngan,et al.  FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancers , 2000 .

[31]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[32]  P. Sugarbaker.  Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[33]  E. Cotte,et al.  Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[34]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Darzi,et al.  Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis , 2007, Annals of Surgical Oncology.

[36]  P. Sugarbaker,et al.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.

[37]  F. Gilly,et al.  [Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia with mitomycin C. Initial experience]. , 1990, Annales de chirurgie.